David Gerber, M.D. Titles and Appointments Co-Director, Simmons Comprehensive Cancer Center Office of Education and Training Professor Endowed Title David Bruton, Jr. Professorship in Clinical Cancer Research School Medical School Department Internal Medicine | Public Health You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography David Gerber, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of the Division of Hematology and Oncology. He serves as Co-Director of Education and Training in the Harold C. Simmons Comprehensive Cancer Center. Originally from Chicago, Dr. Gerber holds a bachelor's degree in history from Yale University in New Haven, Connecticut, where he graduated cum laude. He earned his medical degree at Cornell University Medical College in New York and completed his internship and residency in internal medicine at UT Southwestern, where he served as Chief Resident. He then received advanced training through a fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore. Certified by the American Board of Internal Medicine in medical oncology, Dr. Gerber joined the UT Southwestern faculty in 2007. He is invested in helping patients have a better quality of life. Dr. Gerber is active in research related to lung cancer, including clinical trials. His research has generated more than 250 publications that he has authored or co-authored, including articles and book chapters. His studies have contributed to invitations to lecture both nationally and internationally. He serves on several committees at UT Southwestern. Beyond the institution, he serves as Chair of the Clinical Trials Advisory Committee for the Cancer Prevention and Research Institute of Texas (CPRIT) and is a member of the National Comprehensive Cancer Network (NCCN) Oncology Research Program Investigator Steering Committee. Dr. Gerber holds memberships in several professional organizations, and he has been honored with numerous awards, including being named a Best Doctor in Dallas by D Magazine during the years of 2011-2023. Education Medical School Weill Cornell Graduate School of Medical Science (2000) Residency UT Southwestern Medical Center (2004), Internal Medicine Fellowship Johns Hopkins Hospital (2007), Medical Oncology Research Interest Lung Cancer, Clinical and Translational Research Oncology Outcomes Publications Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials Gerber DE, Wynters CR, Prasad T, Schnel RK, Zhang S, Stinchcombe TE, Villaruz LC, Bauml JM, Iams WT, Patil T, Liu SV, Horn L, Hudak JM, Ross Camidge D Clinical Cancer Research 2025 Mar 31 1103-1108 Virtual Health Care Encounters for Lung Cancer Screening in a Safety-Net Population: Observations From the COVID-19 Pandemic Gwin M, Wahid U, Bhalla S, Kandathil A, Malone S, Natchimuthu VS, Watkins C, Vice L, Chatriand H, Moten H, Tan C, Styrvoky K, Johnson DH, Semlow AR, Lee JL, Browning TG, Mullins M, Santini N, Oliver GH, Zhang S, Gerber DE JCO Clinical Cancer Informatics 2025 Mar Virtual Health Care Encounters for Lung Cancer Screening in a Safety-Net Population: Observations From the COVID-19 Pandemic Gwin ME, Wahid U, Bhalla S, Kandathil A, Malone S, Natchimuthu V, Watkins C, Vice L, Chatriand H, Moten H, Tan C, Styrvoky KC, Johnson DH, Semlow AR, Lee JL, Browning T, Mullins MA, Santini NO, Oliver G, Zhang S, Gerber DE JCO Clinical Cancer Informatics 2025 Mar 9 e2400086 Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer Von Itzstein MS, Rashdan S, Dahlberg SE, Gerber DE, Sandler AB, Schiller J, Johnson DH, Wang Y, Sun Z, Ramalingam SS Oncologist 2025 Mar 30 Identification and Treatment of Lung Cancer Oncogenic Drivers in a Diverse Safety Net Setting Narra K, Ghabach B, Athipatla V, Blackwell JM, Teigen KJ, Bullock JC, Diaz A, Gerber DE, von Itzstein MS Clinical lung cancer 2025 Mar 26 83-92 Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer von Itzstein MS, Burns TF, Dowell JE, Horn L, Camidge DR, York SJ, Eaton KD, Kyle K, Fattah F, Liu J, Mu-Mosley H, Gupta A, Nadeem U, Gao A, Zhang S, Gerber DE Clinical Cancer Research 2025 Feb 31 639-648 Novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models Kowash RR, Sabnani M, Gray LT, Deng Q, Saleh NU, Girard L, Naito Y, Masahiro K, Minna JD, Gerber DE, Koyama S, Liu ZL, Baruah H, Akbay EA Journal for ImmunoTherapy of Cancer 2025 Jan 13 Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief Report Zhang Y, Iyengar P, Montalvo S, Westover KD, Rashdan S, Donthireddy K, Kim J, Dowell JE, Drapkin B, Bhalla S, Chukwuma C, Nadeem U, Ahn C, Timmerman RD, Gerber DE International Journal of Radiation Oncology Biology Physics 2025 Jan 121 68-74 Implantable cardioverter defibrillators in people dying with cancer: A SEER-Medicare analysis of ICD prevalence and association with aggressive end-of-life care Mullins MA, Wang T, Shahan K, Zaha VG, Goswami R, Sulistio M, Gerber DE, Pruitt SL Cancer 2025 Jan 131 Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer von Itzstein MS, Liu J, Mu-Mosley H, Fattah F, Park JY, SoRelle JA, Farrar JD, Gwin ME, Hsiehchen D, Gloria-McCutchen Y, Wakeland EK, Cole S, Bhalla S, Kainthla R, Puzanov I, Switzer B, Daniels GA, Zakharia Y, Shaheen M, Zhang J, Xie Y, Gerber DE JTO Clinical and Research Reports 2025 Jan 6 Results 1-10 of 272 1 2 3 4 5 Next Last Books Featured Books Targeted Therapies for Non-Small Cell Lung Cancer David E. Gerber (2011). Oxford University Press Lung Cancer Apar K. Ganti, David E. Gerber (Ed.) (2014). Oxford University Press Honors & Awards National Cancer Institute(NCI) Director's Award (2023) Leaders in Clinical Excellence Mentoring AwardUT Southwestern (2022) Exceptional Research in Navigation AwardAcademy of Oncology Nurse & Patient Navigators (2018) National Cancer Institute (NCI)Midcareer Investigator Award in Patient-Oriented Research (2016) Top DoctorsCastle Connolly (2015-2023) Best Doctors in DallasD Magazine (2011-2023) Clinical Investigator Team Leadership AwardNational Cancer Institute (2011) Career Development AwardAmerican Society of Clinical Oncology (2009) Professional Associations/Affiliations American Society of Clinical Oncology Dallas County Medical Society Eastern Cooperative Oncology Group International Association for the Study of Lung Cancer Texas Medical Association
